Google and its sister companies are making substantial investments towards artificial intelligence in healthcare; the Trump administration seeks to remove protections for transgender individuals that allow equal access to healthcare; researchers identified 104 high-risk schizophrenia genes.
Google and its sister companies have made a substantial investment, predicted by analysts to be billions of dollars, towards artificial intelligence in the healthcare field, NPR reported. Verily, which was already supplied a billion dollars in funding earlier this year, stands out as a key player; it is currently working on software that can diagnose diabetic retinopathy, tools to monitor blood sugar in diabetic patients, and surgical robots that learn from each operation. Google has an advantage over other companies as it has already collected and compiled data from billions of users.HHS is expected to propose a rule that would facilitate the option for physicians, hospitals, and insurance companies to deny care or coverage to transgender patients as well as women who have had abortions, according to The Hill. The new health regulations could be published as early as next week. The rule is expected to weaken or remove an anti-discrimination provision established in the Affordable Care Act that protected individuals from being denied coverage related to transgender status. Advocates are concerned that the proposal could reverse the progress made in ensuring that transgender patients receive equal access to care.Researchers at Vanderbilt University Department of Molecular Physiology and Biophysics and the Vanderbilt Genetics Institute have identified 104 high-risk genes for schizophrenia, ScienceDaily reported. The discovery supports the idea that schizophrenia is a developmental disease that can potentially be diagnosed and treated before symptoms arise. Future research could be directed towards repurposing current drugs in an effort to improve treatment of the disorder or toward identification of cell types in the brain that are active along the development pathway.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More